Company profile
Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03382340 | phase1_2 | unknown | 2018-02-15 | 2023-10-31 | Immix Biopharma Australia Pty Ltd | IMX-110 in Patients With Advanced Solid Tumors |
| NCT05840835 | phase1_2 | unknown | 2023-02-03 | 2024-01-24 | Immix Biopharma, Inc. | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors |
FDA applications (0)
No records yet.